

NHS Rotherham Clinical Commissioning Group

Primary Care Sub Group – 31 March 2021

Primary Care Committee – 14 April 2021

NHS Rotherham CCG Medicines Management Q3 2020/21 report.

Lead Executive:	Wendy Allott, Chief Finance Officer
Lead Officer:	Stuart Lakin, Head of Medicines Management
Lead GP:	Dr Sophie Holden, SCE GP Lead for Medicines Management

Purpose:

To introduce the NHS Rotherham CCG Medicines Management Teams Q3 2020/21 report.

Background:

The Medicines Management Team monitors and advises on all aspects of prescribing that is attributed to NHS Rotherham CCG.

Practice prescribing was very volatile in both activity and cost for the first six months of this financial year, but both cost growth and volume growth have stabilised in Q3 2020/21. Rotherham CCG's cost and volume growth compare favourably against the national picture and against that of similar CCGs

There is currently no transfer of non-PBR drug costs to the CCG due to the total-block arrangements". However, the system for tracking and recording non-PBR drugs (Blueteq) is still operational in preparation for the ending of the total-block arrangements.

The services managing the prescribing and supply of continence and stoma appliances, nutritional products including specialist baby milks, and wound care products, have all performed well over YTD 2020/21 despite the unusual working conditions.

Despite the challenging working arrangements several QIPP projects have been commenced in 2020/21.

Analysis of key issues and of risks

See attached report

Patient, Public and Stakeholder Involvement:

Not applicable

Equality Impact:

Not applicable

Financial Implications:
<p>Prescribing is the second largest area of expenditure for a CCG. Whilst the financial risk of this area of expenditure resides with the CCG, the CCG has little influence over the “prescribers” whose actions impact on prescribing expenditure.</p> <p>Prescribing costs are influenced by a wide range of factors that are often outside of the individual clinician’s control such as:</p> <ul style="list-style-type: none"> • National guidance (NICE etc) • New clinical evidence • Drug shortages – resulting in patients having to prescribing less cost effective alternatives • Drugs not available at drug tariff price (NHS contract price) <p>Drugs are global commodities and supply chains into the UK are international. The ever increasing number of drug shortages / supply problems and the inability to obtain drugs at drug tariff price, will all impact on a CCGs prescribing costs.</p> <p>The MMT has to engage with prescribers to get them to accept ownership of the financial impact of their prescribing, even though increased prescribing costs will have little direct impact on the clinician.</p>
Human Resource Implications:
Not applicable
Procurement Advice:
Not applicable
Data Protection Impact Assessment
Not applicable
Approval history:
Not applicable
Recommendations:
For the committee to note the content of the report.
Paper is for information